Roger M. Bjerke

1.0k total citations
29 papers, 600 citations indexed

About

Roger M. Bjerke is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Roger M. Bjerke has authored 29 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Roger M. Bjerke's work include Radiopharmaceutical Chemistry and Applications (19 papers), Prostate Cancer Treatment and Research (5 papers) and DNA Repair Mechanisms (3 papers). Roger M. Bjerke is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (19 papers), Prostate Cancer Treatment and Research (5 papers) and DNA Repair Mechanisms (3 papers). Roger M. Bjerke collaborates with scholars based in Norway, Germany and United States. Roger M. Bjerke's co-authors include Alan Cuthbertson, Urs B. Hagemann, Jenny Karlsson, Olav B. Ryan, Dominik Mumberg, Alexander Kristian, Christine Ellingsen, Derek Grant, Hartwig Hennekes and Véronique Cruciani and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Roger M. Bjerke

29 papers receiving 582 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger M. Bjerke Norway	12	448	282	166	79	54	29	600
R. Keith Frank United States	9	596 1.3×	218 0.8×	153 0.9×	87 1.1×	79 1.5×	12	730
Urs B. Hagemann Germany	17	526 1.2×	321 1.1×	272 1.6×	202 2.6×	59 1.1×	46	858
Kwon Joong Yong United States	11	360 0.8×	211 0.7×	132 0.8×	158 2.0×	51 0.9×	12	548
Jörgen Elgqvist Sweden	16	862 1.9×	418 1.5×	199 1.2×	89 1.1×	125 2.3×	27	1.0k
Sophie Poty France	15	475 1.1×	172 0.6×	215 1.3×	117 1.5×	80 1.5×	25	720
Raffaella M. Schmid Switzerland	9	302 0.7×	166 0.6×	112 0.7×	88 1.1×	21 0.4×	11	429
Robert Freudenberg Germany	15	364 0.8×	195 0.7×	125 0.8×	115 1.5×	136 2.5×	50	615
Alejandro Amor‐Coarasa United States	15	671 1.5×	328 1.2×	332 2.0×	86 1.1×	58 1.1×	33	873
Roswitha Runge Germany	15	448 1.0×	267 0.9×	218 1.3×	134 1.7×	45 0.8×	41	646
Christine Ellingsen Norway	17	512 1.1×	196 0.7×	217 1.3×	104 1.3×	29 0.5×	32	774

Countries citing papers authored by Roger M. Bjerke

Since Specialization

Citations

This map shows the geographic impact of Roger M. Bjerke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger M. Bjerke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger M. Bjerke more than expected).

Fields of papers citing papers by Roger M. Bjerke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger M. Bjerke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger M. Bjerke. The network helps show where Roger M. Bjerke may publish in the future.

Co-authorship network of co-authors of Roger M. Bjerke

This figure shows the co-authorship network connecting the top 25 collaborators of Roger M. Bjerke. A scholar is included among the top collaborators of Roger M. Bjerke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger M. Bjerke. Roger M. Bjerke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schatz, Christoph A., Sabine Zitzmann-Kolbe, Ingrid Moen, et al.. (2024). Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer. Clinical Cancer Research. 30(11). 2531–2544. 5 indexed citations

Zitzmann-Kolbe, Sabine, Alexander Kristian, Dieter Zopf, et al.. (2023). A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies. Molecular Cancer Therapeutics. 22(9). 1073–1086. 3 indexed citations

Mobergslien, Anne, Ingrid Moen, Alexander Kristian, et al.. (2022). Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. Frontiers in Medicine. 9. 1033303–1033303. 6 indexed citations

Hagemann, Urs B., Stefanie Hammer, Roger M. Bjerke, et al.. (2020). Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy. Cancer Biotherapy and Radiopharmaceuticals. 35(7). 497–510. 49 indexed citations

Hagemann, Urs B., Christine Ellingsen, Joachim Schuhmacher, et al.. (2019). Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clinical Cancer Research. 25(15). 4723–4734. 86 indexed citations

Hammer, Stefanie, Urs B. Hagemann, Sabine Zitzmann-Kolbe, et al.. (2019). Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clinical Cancer Research. 26(8). 1985–1996. 94 indexed citations

Karlsson, Jenny, Christine Ellingsen, Véronique Cruciani, et al.. (2019). Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model. Pharmaceuticals. 12(4). 155–155. 29 indexed citations

Hagemann, Urs B., Véronique Cruciani, Antje M. Wengner, et al.. (2019). Synergistic Effect of a Mesothelin-Targeted ²²⁷Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models. Journal of Nuclear Medicine. 60(9). 1293–1300. 40 indexed citations

Hagemann, Urs B., Alexander Kristian, Christine Ellingsen, et al.. (2019). Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344. International Journal of Radiation Oncology*Biology*Physics. 105(2). 410–422. 18 indexed citations

10.

Hammer, Stefanie, Urs B. Hagemann, Sabine Zitzmann-Kolbe, et al.. (2018). Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models. Cancer Research. 78(13_Supplement). 844–844. 4 indexed citations

11.

Hagemann, Urs B., Steinar Uran, Derek Grant, et al.. (2017). Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate inin vitroandin vivomodels of renal cell carcinoma. Oncotarget. 8(34). 56311–56326. 41 indexed citations

12.

Hagemann, Urs B., Anette Sommer, Alexander Kristian, et al.. (2017). Abstract 5199: Preclinical activity of the FGFR2-targeted thorium-227 conjugate in preclinical models of colorectal, gastric and triple-negative breast cancer. Cancer Research. 77(13_Supplement). 5199–5199. 4 indexed citations

13.

Karlsson, Jenny, Urs B. Hagemann, Christoph A. Schatz, et al.. (2017). Abstract 5857: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in a HER2 positive orthotopic bone model. Cancer Research. 77(13_Supplement). 5857–5857. 6 indexed citations

14.

Hagemann, Urs B., Ellen Wang, Jenny Karlsson, et al.. (2016). In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 15(10). 2422–2431. 62 indexed citations

15.

Ramdahl, Thomas, et al.. (2016). An efficient chelator for complexation of thorium-227. Bioorganic & Medicinal Chemistry Letters. 26(17). 4318–4321. 56 indexed citations

16.

Hagemann, Urs B., Jenny Karlsson, Roger M. Bjerke, et al.. (2016). Abstract 591: A novel high energy alpha-pharmaceutical: In vitro and in vivo potency of a mesothelin-targeted thorium-227 conjugate (TTC) in a model of bone disease. Cancer Research. 76(14_Supplement). 591–591. 5 indexed citations

17.

Evans, Paul M., et al.. (2012). Abstract 357: Nonclinical tumor efficacy studies of [18F]AH113804, a novel PET imaging agent with high affinity for the human c-Met receptor. Cancer Research. 72(8_Supplement). 357–357. 2 indexed citations

18.

Bajaj, Anshika, Victoria Cotero, Kenneth Fish, et al.. (2012). Identification of the Protein Target of Myelin-Binding Ligands by Immunohistochemistry and Biochemical Analyses. Journal of Histochemistry & Cytochemistry. 61(1). 19–30. 26 indexed citations

19.

Myrset, Astrid Hilde, et al.. (2010). Design and Characterization of Targeted Ultrasound Microbubbles for Diagnostic Use. Ultrasound in Medicine & Biology. 37(1). 136–150. 22 indexed citations

20.

Moestue, Siver Andreas, Andrew Healey, Roger M. Bjerke, et al.. (2009). Whole‐body section fluorescence imaging – a novel method for tissue distribution studies of fluorescent substances. Contrast Media & Molecular Imaging. 4(2). 73–80. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact